CU24603B1 - Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios - Google Patents
Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratoriosInfo
- Publication number
- CU24603B1 CU24603B1 CU2019000101A CU20190101A CU24603B1 CU 24603 B1 CU24603 B1 CU 24603B1 CU 2019000101 A CU2019000101 A CU 2019000101A CU 20190101 A CU20190101 A CU 20190101A CU 24603 B1 CU24603 B1 CU 24603B1
- Authority
- CU
- Cuba
- Prior art keywords
- imidazopyrimidines
- useful
- treatment
- respiratory disorders
- substituted diazabicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>La presente solicitud se refiere a imidazopirimidinas diazabicíclicas sustituidas de fórmula I:</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>,útiles en el tratamiento de trastornos respiratorios. Se refiere también a los procedimientos de preparación de las mismas.</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17176046 | 2017-06-14 | ||
EP17193252 | 2017-09-26 | ||
PCT/EP2018/064977 WO2018228907A1 (de) | 2017-06-14 | 2018-06-07 | Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20190101A7 CU20190101A7 (es) | 2020-10-20 |
CU24603B1 true CU24603B1 (es) | 2022-06-06 |
Family
ID=62492660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2019000101A CU24603B1 (es) | 2017-06-14 | 2018-06-07 | Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios |
Country Status (33)
Country | Link |
---|---|
US (2) | US11098063B2 (es) |
EP (1) | EP3638675B1 (es) |
JP (2) | JP6896113B2 (es) |
KR (1) | KR102364134B1 (es) |
CN (4) | CN110719911B (es) |
AR (1) | AR112099A1 (es) |
AU (1) | AU2018283331B2 (es) |
BR (1) | BR112019026450A2 (es) |
CA (1) | CA3066942A1 (es) |
CL (1) | CL2019003650A1 (es) |
CO (1) | CO2019014047A2 (es) |
CR (1) | CR20190563A (es) |
CU (1) | CU24603B1 (es) |
DO (1) | DOP2019000308A (es) |
EA (1) | EA202090043A1 (es) |
EC (1) | ECSP19088492A (es) |
GE (1) | GEP20227366B (es) |
HR (1) | HRP20240678T1 (es) |
HU (1) | HUE066512T2 (es) |
IL (1) | IL271117B (es) |
JO (1) | JOP20190284A1 (es) |
MA (1) | MA49368A (es) |
MX (2) | MX2019014983A (es) |
NI (1) | NI201900126A (es) |
PE (1) | PE20200016A1 (es) |
PH (1) | PH12019502828A1 (es) |
PL (1) | PL3638675T3 (es) |
RS (1) | RS65543B1 (es) |
SG (1) | SG11201911508XA (es) |
TW (1) | TWI801388B (es) |
UA (1) | UA125186C2 (es) |
UY (1) | UY37773A (es) |
WO (1) | WO2018228907A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180088462A (ko) | 2015-12-10 | 2018-08-03 | 바이엘 파마 악티엔게젤샤프트 | 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체 |
JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
CA3147105A1 (en) * | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
TW202108135A (zh) | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 治療睡眠呼吸中止症之α2-腎上腺素受體亞型C (α-2C)拮抗劑與TASK1/3通道阻斷劑之組合 |
CN114929694A (zh) | 2019-11-06 | 2022-08-19 | 拜耳公司 | 肾上腺素能受体adrac2拮抗剂 |
US20240000767A1 (en) * | 2020-07-06 | 2024-01-04 | Bayer Aktiengesellschaft | Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonist with a task1/3 channel blocker for the treatment of sleep apnea |
GB202101734D0 (en) * | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
KR20240127384A (ko) | 2021-12-22 | 2024-08-22 | 바이엘 악티엔게젤샤프트 | 수면 무호흡의 치료를 위한 task1/3 채널 차단제와 노르에피네프린 재흡수 억제제의 조합물 |
KR20240124998A (ko) | 2021-12-22 | 2024-08-19 | 바이엘 악티엔게젤샤프트 | 수면 무호흡의 치료를 위한 task1/3 채널 차단제와 무스카린성 수용체 길항제의 조합물 |
AU2022420723A1 (en) | 2021-12-22 | 2024-07-04 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a p2x3 receptor antagonist for the treatment of sleep apnea |
KR20240132345A (ko) | 2022-01-07 | 2024-09-03 | 바이엘 악티엔게젤샤프트 | 수면 무호흡의 치료를 위한 2,3-디히드로벤조[b][1,4]디옥신-2-일메틸)피페라진-1-일 유도체 |
CN118785902A (zh) | 2022-01-07 | 2024-10-15 | 拜耳公司 | 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C拮抗剂 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
US6552037B2 (en) | 2000-06-30 | 2003-04-22 | Neurogen Corporation | 2-Substituted imidazo[1,2-A]pyridine derivatives |
GB0017256D0 (en) | 2000-07-13 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10247269A1 (de) | 2002-10-10 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine |
US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
CN101636154B (zh) * | 2006-04-27 | 2011-12-14 | 塞诺菲-安万特德国有限公司 | Task-1和task-3离子通道抑制剂 |
EP2049110B1 (en) * | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
JP5774982B2 (ja) | 2008-05-19 | 2015-09-09 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | イミダゾ[1,2−a]ピリジン化合物 |
US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
EP2547678B1 (en) | 2010-03-18 | 2016-03-16 | Institut Pasteur Korea | Anti-infective compounds |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
PE20130779A1 (es) | 2010-07-09 | 2013-06-21 | Bayer Ip Gmbh | Pirimidinas y triazinas condensadas y su uso |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
EP2671582B1 (en) | 2011-02-01 | 2016-07-13 | Kyowa Hakko Kirin Co., Ltd. | Ring-fused heterocyclic derivative |
EP2691392A1 (en) | 2011-03-31 | 2014-02-05 | EMBLEM Technology Transfer GmbH | Imidazo [1,2-a]pyridine compounds for use in therapy |
US9029389B2 (en) | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
BR112014005583A2 (pt) | 2011-09-12 | 2017-03-21 | Sanofi Sa | 4,5,6,7-tetra-hidro-1h-pirazolo[4,3-c]piridinas substituídas com indanila, seu uso como medicamento, e preparações farmacêuticas que as contêm |
EA025240B1 (ru) | 2011-09-16 | 2016-12-30 | Санофи | ЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРО-1H-ПИРАЗОЛО[4,3-c]ПИРИДИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, СОДЕРЖАЩИЕ ИХ |
KR20140077912A (ko) | 2011-09-16 | 2014-06-24 | 사노피 | 치환된 4,5,6,7-테트라하이드로-1H-피라졸로[4,3-c]피리딘, 약물로서의 그 용도, 및 그를 포함한 약제학적 제제 |
CA2860933C (en) | 2012-02-03 | 2020-01-14 | Sanofi | Fused pyrroledicarboxamides and their use as pharmaceuticals |
SG11201509650YA (en) * | 2013-05-24 | 2015-12-30 | Iomet Pharma Ltd | Slc2a transporter inhibitors |
CN106103446B (zh) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
WO2016085784A1 (en) | 2014-11-26 | 2016-06-02 | Merck Sharp & Dohme Corp. | Methyl diazepane orexin receptor antagonists |
JP2018012645A (ja) * | 2014-11-26 | 2018-01-25 | 持田製薬株式会社 | 新規ジアザビシクロ誘導体 |
US9994570B2 (en) * | 2014-11-26 | 2018-06-12 | Merck Sharp & Dohme Corp. | Bridged diazepane orexin receptor antagonists |
TWI585785B (zh) * | 2014-11-26 | 2017-06-01 | Murata Manufacturing Co | Electronic parts manufacturing methods, electronic components and electronic devices |
JP2018016544A (ja) | 2014-12-03 | 2018-02-01 | 持田製薬株式会社 | 新規ジアザビシクロ[2.2.2]オクタン誘導体 |
EP3353180B1 (en) | 2015-09-24 | 2022-03-16 | F. Hoffmann-La Roche AG | Bicyclic compounds as atx inhibitors |
WO2017097671A1 (de) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung |
KR20180088462A (ko) | 2015-12-10 | 2018-08-03 | 바이엘 파마 악티엔게젤샤프트 | 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체 |
JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
CA3147105A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
TW202108135A (zh) | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 治療睡眠呼吸中止症之α2-腎上腺素受體亞型C (α-2C)拮抗劑與TASK1/3通道阻斷劑之組合 |
-
2017
- 2017-06-16 JO JOP/2019/0284A patent/JOP20190284A1/ar unknown
-
2018
- 2018-06-07 KR KR1020207000676A patent/KR102364134B1/ko active IP Right Grant
- 2018-06-07 CN CN201880039548.3A patent/CN110719911B/zh active Active
- 2018-06-07 GE GEAP201815256A patent/GEP20227366B/en unknown
- 2018-06-07 WO PCT/EP2018/064977 patent/WO2018228907A1/de active Application Filing
- 2018-06-07 EP EP18728646.3A patent/EP3638675B1/de active Active
- 2018-06-07 AU AU2018283331A patent/AU2018283331B2/en active Active
- 2018-06-07 SG SG11201911508XA patent/SG11201911508XA/en unknown
- 2018-06-07 CN CN202211199746.0A patent/CN115554299A/zh active Pending
- 2018-06-07 MX MX2019014983A patent/MX2019014983A/es unknown
- 2018-06-07 HU HUE18728646A patent/HUE066512T2/hu unknown
- 2018-06-07 EA EA202090043A patent/EA202090043A1/ru unknown
- 2018-06-07 RS RS20240581A patent/RS65543B1/sr unknown
- 2018-06-07 CR CR20190563A patent/CR20190563A/es unknown
- 2018-06-07 BR BR112019026450-7A patent/BR112019026450A2/pt unknown
- 2018-06-07 CU CU2019000101A patent/CU24603B1/es unknown
- 2018-06-07 HR HRP20240678TT patent/HRP20240678T1/hr unknown
- 2018-06-07 MA MA049368A patent/MA49368A/fr unknown
- 2018-06-07 CN CN202211200547.7A patent/CN115554300A/zh active Pending
- 2018-06-07 PL PL18728646.3T patent/PL3638675T3/pl unknown
- 2018-06-07 US US16/622,233 patent/US11098063B2/en active Active
- 2018-06-07 JP JP2019569416A patent/JP6896113B2/ja active Active
- 2018-06-07 CN CN202211200627.2A patent/CN115583959B/zh active Active
- 2018-06-07 CA CA3066942A patent/CA3066942A1/en active Pending
- 2018-06-07 PE PE2019002541A patent/PE20200016A1/es unknown
- 2018-06-07 UA UAA202000222A patent/UA125186C2/uk unknown
- 2018-06-12 TW TW107120117A patent/TWI801388B/zh active
- 2018-06-13 AR ARP180101619A patent/AR112099A1/es unknown
- 2018-06-14 UY UY0001037773A patent/UY37773A/es unknown
-
2019
- 2019-12-02 IL IL271117A patent/IL271117B/en unknown
- 2019-12-11 MX MX2022012716A patent/MX2022012716A/es unknown
- 2019-12-12 CL CL2019003650A patent/CL2019003650A1/es unknown
- 2019-12-12 NI NI201900126A patent/NI201900126A/es unknown
- 2019-12-12 CO CONC2019/0014047A patent/CO2019014047A2/es unknown
- 2019-12-12 EC ECSENADI201988492A patent/ECSP19088492A/es unknown
- 2019-12-13 PH PH12019502828A patent/PH12019502828A1/en unknown
- 2019-12-13 DO DO2019000308A patent/DOP2019000308A/es unknown
-
2021
- 2021-06-04 JP JP2021094338A patent/JP2021127346A/ja active Pending
- 2021-07-16 US US17/305,927 patent/US20220017540A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24603B1 (es) | Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios | |
CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
NI201700095A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
NI201800128A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
DOP2016000107A (es) | PIRROLO[1,2-f][1,2,4]TRIAZINAS ÚTILES PARA TRATAR INFECCIONES POR EL VIRUS SINCITIAL RESPIRATORIO. | |
ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
CR20170008A (es) | Compuestos de [1,2,4] triazol e imidazol sustituidos | |
GT201700058A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
UY37947A (es) | Amidas de imidazopiridina sustituidas y su uso | |
UY35274A (es) | Compuestos y métodos para tratar infecciones bacterianas | |
CL2015003195A1 (es) | Derivados de purina como agonistas del receptor cb2. | |
EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
CR20160016A (es) | Pirazolpiridinas sustituidas | |
CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
CL2017003025A1 (es) | Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios. | |
CU20180044A7 (es) | Derivados novedosos de diamino piridina | |
CL2017002148A1 (es) | Derivados de tetrahidropiranil benzamida | |
EA201400786A1 (ru) | Карбоциклические нуклеозиды, их фармацевтическое применение и композиции | |
NI201500172A (es) | Composiciones farmacéuticas | |
BR112015030589A8 (pt) | formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas | |
AR095353A1 (es) | Compuesto |